These findings underscore the importance of metabolic profiling in optimizing rhGH therapy and suggest that targeting insulin resistance could be a promising strategy to enhance growth outcomes, supported by evidence that suppressing hyperinsulinemia restores GH secretion and action. The gene discussed is GH1; the disease is Insulin resistance.